The mRNA Cancer Vaccines and Therapeutics Market was valued at USD 136.84 million in 2019 and is estimated to be valued at USD 943.99 million by 2027, growing at a CAGR of 24.4% through the forecast period. A vaccine is a biological recipe that is designed to provide acquired immunity to a target disease. It stimulates the body’s immune system to recognize the disease-causing microorganism as a threat and destroy it. Its administration is known as vaccination, the most effective method of preventing infectious diseases. mRNA vaccines and therapies are used for the prevention and treatment of serious health conditions such as cancer, infectious diseases such as Acquired Immunodeficiency Syndrome (AIDS), and respiratory diseases.

Recent breakthroughs in Cancer Immunotherapy have demonstrated that powerful antitumor responses can be achieved by activating antigen-specific T cells in a variety of cancer settings. Despite these advances, many patients’ cancer responds only partially or does not respond at all to these anti-cancer therapies. An approach to solve this is to administer a cancer vaccine that encodes for peptides containing mutations found in their cancer, that is, to create a personalized cancer vaccine composed of neoantigens unique to a patient’s tumor.

Key industry players are working to create individualized, mRNA-based personalized cancer vaccines to deliver one custom-tailored medicine for one patient at a time. Through next-generation sequencing, they can identify mutations found on a patient’s cancer cells, called neoepitopes. Neoepitopes can help the immune system tell the difference between cancer cells and normal cells. Using algorithms developed by our in-house Bioinformatics team, 20 neoepitopes present on the patient’s cancer can be predicted that should elicit the strongest immune response, based on unique characteristics of the patient’s immune system and cancer’s particular mutations. Vaccine producers then create a vaccine that encodes for each of these mutations and loads them onto a single mRNA molecule. 

Once injected, the vaccine can direct the patient’s cells to express the selected neoepitopes. Eventually, this can help the patient’s immune system better recognize cancer cells as foreign and destroy them. Leveraging rapid cycle time, small-batch manufacturing technique and Digital infrastructure, mRNA cancer vaccines, and therapeutics market players work to manufacture and supply each individually manufactured personalized cancer vaccine to the patient rapidly.

The rise in the prevalence of cancer, genetic disorders, and an increase in awareness about vaccination drive the global mRNA cancer vaccines and therapeutics market revenue growth.

In terms of indication, the global mRNA cancer vaccines and therapeutics market can be classified into Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas, and others.

According to the National Cancer Institute (NCI), cancer is among the leading causes of death worldwide, and the number of new cases per year is expected to rise to 23.6 million by 2030. According to the World Health Organization (WHO), currently, 10,000 human diseases are known to be monogenic, caused by modifications in a single gene in human DNA. Nearly 10 of 1000 births across the globe witness some form of single-gene diseases.

Based on end-user, the global mRNA cancer vaccines and therapeutics market can be categorized into hospitals & clinics, ambulatory surgical centers, research institutes, and others. The hospitals & clinics segment is likely to account for a major share of the global mRNA cancer vaccines and therapeutics market by 2027, owing to increase in the number of patients with respiratory diseases, cancer, and infectious diseases

In terms of region, the global mRNA cancer vaccines and therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global mRNA cancer vaccines and therapeutics market during the forecast period.

Increase in demand for mRNA cancer vaccines and therapeutics, the presence of prominent players operating in the U.S., and an exponential rise in the number of cancer cases due to shifting lifestyles in the U.S. are anticipated to drive the mRNA cancer vaccines and therapeutics market in North America.

The global mRNA cancer vaccines and therapeutics market is highly fragmented, with a large number of domestic players accounting for major market share. Key players operating in the global mRNA cancer vaccines and therapeutics market include Immuno-Oncology" target="_blank" rel="noopener">Moderna Therapeutics, eTheRNA, BioNTech, CureVac, In-Cell-Art, Translate Bio, Tiba Biotechnology, Argos Therapeutics, Sangamo Therapeutics, and Ethris.

Market Segmentation:

By Application (Revenue, USD Million; 2017-2027)

  • Adeno Carcinomas
  • Mucinous Carcinomas
  • Adenosquamous Carcinomas

By End-user (Revenue, USD Million; 2017-2027)

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Research Institutes
  • Others

By Region (Revenue, USD Million; 2017-2027)

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • France
    • U.K
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

REQUEST SAMPLE REPORT

Get Free Sample Report

REQUEST SAMPLE REPORT

REQUEST FOR CUSTOMIZATION

Tailor-make Your Research

REQUEST CUSTOMIZATION

Key questions answered by the report